India’s Vaccine Manufacturing Capacity: The Pandemic Lesson the World Still Hasn’t Fully Learned

India’s pharmaceutical and vaccine manufacturing sector, often described as the “pharmacy of the world” for its scale of generic drug and vaccine production, played a consequential and at times controversial role during the COVID-19 pandemic, simultaneously serving as a critical global vaccine supply source and becoming the centre of significant international tension when India temporarily restricted vaccine exports during its own severe domestic pandemic wave.

The Scale of Indian Manufacturing Capacity

India’s vaccine manufacturing sector, anchored by several large domestic manufacturers with substantial production capacity, has historically supplied a very large share of the vaccine doses used in global immunisation programmes for diseases beyond COVID-19, including a substantial share of vaccines distributed through international health partnerships serving lower-income countries. This existing manufacturing scale and infrastructure proved genuinely valuable during the COVID-19 pandemic, allowing India to rapidly scale domestic vaccine production and supply both its own population and, for a period, substantial international export volumes.

The Export Restriction Controversy

When India experienced a severe domestic COVID-19 wave, the government temporarily restricted vaccine exports to prioritise domestic immunisation needs, a decision that, while defensible from a domestic public health perspective given the severity of the wave India was experiencing, created significant disruption for international vaccine distribution programmes that had built supply plans around continued Indian export volumes, generating considerable international criticism and prompting broader discussion about the wisdom of concentrating such a large share of global vaccine manufacturing capacity within any single country’s domestic production base.

A global health system this dependent on a single country’s manufacturing capacity will always face this exact tension during any country’s domestic crisis: the same concentration that makes the system efficient in normal times makes it fragile precisely when global supply security matters most.

The Lesson Only Partially Absorbed

The pandemic experience prompted considerable international discussion about diversifying global vaccine manufacturing capacity beyond its historical concentration in a small number of countries, including India, alongside renewed discussion about technology transfer mechanisms that could enable additional manufacturing capacity in other regions, particularly Africa, which had historically depended almost entirely on imported vaccines. Progress on this diversification agenda has been real but incremental, with several new regional manufacturing initiatives announced and partially underway, though the scale of genuinely diversified, geographically distributed global vaccine manufacturing capacity remains considerably short of what the pandemic experience suggested would be prudent for global health security.

India’s Continuing Strategic Position

India’s own strategic position within this global landscape remains genuinely strong, with continued investment in expanding domestic vaccine and pharmaceutical manufacturing capacity, alongside growing emphasis on developing indigenous vaccine platform technologies rather than relying primarily on technology licensed from international partners. Whether India leverages this position primarily as a commercial manufacturing advantage or also as a more active contributor to genuinely diversified global health security architecture will significantly shape how the next major global health crisis, whenever it occurs, unfolds for the lower-income countries that depend most heavily on Indian-manufactured vaccines and medicines.